A Comprehensive Network Pharmacology-Based Strategy to Investigate Multiple Mechanisms of HeChan Tablet on Lung Cancer.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
12
2019
revised:
03
05
2020
accepted:
14
05
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
HeChan tablet (HCT) is a traditional Chinese medicine preparation extensively prescribed to treat lung cancer in China. However, the pharmacological mechanisms of HCT on lung cancer remain to be elucidated. A comprehensive network pharmacology-based strategy was conducted to explore underlying mechanisms of HCT on lung cancer. Putative targets and compounds of HCT were retrieved from TCMSP and BATMAN-TCM databases; related genes of lung cancer were retrieved from OMIM and DisGeNET databases; known therapeutic target genes of lung cancer were retrieved from TTD and DrugBank databases; PPI networks among target genes were constructed to filter hub genes by STRING. Furthermore, the pathway and GO enrichment analysis of hub genes was performed by clusterProfiler, and the clinical significance of hub genes was identified by The Cancer Genome Atlas. A total of 206 compounds and 2,433 target genes of HCT were obtained. 5,317 related genes of lung cancer and 77 known therapeutic target genes of lung cancer were identified. 507 unique target genes were identified among HCT-related genes of lung cancer and 34 unique target genes were identified among HCT-known therapeutic target genes of lung cancer. By PPI networks, 11 target genes AKT1, TP53, MAPK8, JUN, EGFR, TNF, INS, IL-6, MYC, VEGFA, and MAPK1 were identified as major hub genes. IL-6, JUN, EGFR, and MYC were shown to associate with the survival of lung cancer patients. Five compounds of HCT， quercetin, luteolin, kaempferol, beta-sitosterol, and baicalein were recognized as key compounds of HCT on lung cancer. The gene enrichment analysis implied that HCT probably benefitted patients with lung cancer by modulating the MAPK and PI3K-Akt pathways. This study predicted pharmacological and molecular mechanisms of HCT against lung cancer and could pave the way for further experimental research and clinical application of HCT.
Sections du résumé
BACKGROUND
BACKGROUND
HeChan tablet (HCT) is a traditional Chinese medicine preparation extensively prescribed to treat lung cancer in China. However, the pharmacological mechanisms of HCT on lung cancer remain to be elucidated.
METHODS
METHODS
A comprehensive network pharmacology-based strategy was conducted to explore underlying mechanisms of HCT on lung cancer. Putative targets and compounds of HCT were retrieved from TCMSP and BATMAN-TCM databases; related genes of lung cancer were retrieved from OMIM and DisGeNET databases; known therapeutic target genes of lung cancer were retrieved from TTD and DrugBank databases; PPI networks among target genes were constructed to filter hub genes by STRING. Furthermore, the pathway and GO enrichment analysis of hub genes was performed by clusterProfiler, and the clinical significance of hub genes was identified by The Cancer Genome Atlas.
RESULT
RESULTS
A total of 206 compounds and 2,433 target genes of HCT were obtained. 5,317 related genes of lung cancer and 77 known therapeutic target genes of lung cancer were identified. 507 unique target genes were identified among HCT-related genes of lung cancer and 34 unique target genes were identified among HCT-known therapeutic target genes of lung cancer. By PPI networks, 11 target genes AKT1, TP53, MAPK8, JUN, EGFR, TNF, INS, IL-6, MYC, VEGFA, and MAPK1 were identified as major hub genes. IL-6, JUN, EGFR, and MYC were shown to associate with the survival of lung cancer patients. Five compounds of HCT， quercetin, luteolin, kaempferol, beta-sitosterol, and baicalein were recognized as key compounds of HCT on lung cancer. The gene enrichment analysis implied that HCT probably benefitted patients with lung cancer by modulating the MAPK and PI3K-Akt pathways.
CONCLUSION
CONCLUSIONS
This study predicted pharmacological and molecular mechanisms of HCT against lung cancer and could pave the way for further experimental research and clinical application of HCT.
Identifiants
pubmed: 32595734
doi: 10.1155/2020/7658342
pmc: PMC7277035
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7658342Informations de copyright
Copyright © 2020 Zhenjie Zhuang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Pharmacol Ther. 2014 May;142(2):164-75
pubmed: 24333502
Nat Rev Immunol. 2015 Jun;15(6):362-74
pubmed: 26008591
Sci Rep. 2014 Feb 24;4:4154
pubmed: 24561634
Mol Biosyst. 2014 May;10(5):1014-22
pubmed: 24492828
Cell. 2017 Aug 10;170(4):605-635
pubmed: 28802037
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Toxicol Appl Pharmacol. 2014 Dec 1;281(2):230-41
pubmed: 25448439
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136
Nucleic Acids Res. 2016 May 5;44(8):3772-87
pubmed: 27025651
Lung Cancer. 2018 Nov;125:22-28
pubmed: 30429024
Antioxid Redox Signal. 2011 Aug 1;15(3):719-61
pubmed: 20969480
Int J Oncol. 2015 Mar;46(3):1149-58
pubmed: 25586525
Arch Toxicol. 2015 Aug;89(8):1227-40
pubmed: 25983263
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Nucleic Acids Res. 2018 Mar 16;46(5):2699
pubmed: 29425356
Curr Opin Genet Dev. 2008 Feb;18(1):73-9
pubmed: 18325754
J Exp Clin Cancer Res. 2018 Jul 27;37(1):173
pubmed: 30053872
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
FEBS J. 2010 Jan;277(2):316-26
pubmed: 19922467
Genome Biol. 2014;15(12):550
pubmed: 25516281
Rejuvenation Res. 2015 Aug;18(4):313-25
pubmed: 25687091
Nutr Cancer. 2015;67(8):1214-20
pubmed: 26473555
Br J Pharmacol. 2014 Jun;171(11):2842-53
pubmed: 24471765
Curr Protein Pept Sci. 2019;20(3):251-264
pubmed: 29895243
Oncol Rep. 2015 Nov;34(5):2351-6
pubmed: 26323894
Gene. 2006 Jan 17;366(1):2-16
pubmed: 16377102
Mol Cancer Ther. 2017 Aug;16(8):1645-1657
pubmed: 28566434
Lung Cancer. 2017 Aug;110:63-67
pubmed: 28676221
Appl Microbiol Biotechnol. 2010 Dec;88(6):1269-75
pubmed: 20717667
Nucleic Acids Res. 2013 Jan;41(Database issue):D808-15
pubmed: 23203871
Expert Opin Biol Ther. 2020 Jan;20(1):23-33
pubmed: 31714156
BMC Cancer. 2016 Sep 01;16:707
pubmed: 27586635
J Exp Clin Cancer Res. 2015 May 07;34:41
pubmed: 25948105
Lancet Respir Med. 2015 Apr;3(4):319-27
pubmed: 25801412
Nucleic Acids Res. 2017 Jan 4;45(D1):D833-D839
pubmed: 27924018
Trends Pharmacol Sci. 2016 Nov;37(11):887-903
pubmed: 27717507
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D514-7
pubmed: 15608251
Phytother Res. 2013 Oct;27(10):1481-8
pubmed: 23172826
Oncogene. 2006 Jan 12;25(2):271-7
pubmed: 16158054
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2010 Jun;30(6):607-10
pubmed: 20815276
Nat Rev Rheumatol. 2016 Jan;12(1):49-62
pubmed: 26656660
Nucleic Acids Res. 2018 Jan 4;46(D1):D1121-D1127
pubmed: 29140520
Int J Cancer. 2015 Feb 1;136(3):547-59
pubmed: 24947242
Nutrients. 2017 Jun 13;9(6):
pubmed: 28608828
J Biol Chem. 2015 Jul 10;290(28):17495-504
pubmed: 26023239
Sci Rep. 2017 Sep 26;7(1):12317
pubmed: 28951614
Evid Based Complement Alternat Med. 2013;2013:548498
pubmed: 23690848
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393891
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Lung Cancer. 2012 Feb;75(2):167-77
pubmed: 21802163
Oncol Lett. 2017 Jun;13(6):4657-4660
pubmed: 28599466
Arch Toxicol. 2015 Jun;89(6):867-82
pubmed: 25690731
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Cell Cycle. 2017 Aug 18;16(16):1489-1498
pubmed: 28737478
Autoimmunity. 2018 Jun;51(4):191-198
pubmed: 29869537
Chin Med. 2015 Jul 19;10:19
pubmed: 26191080
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W510-7
pubmed: 23761452
Arch Bronconeumol. 2018 Jan;54(1):10-17
pubmed: 29079040
Cancer Med. 2016 Nov;5(11):3156-3165
pubmed: 27704720
Clin Lung Cancer. 2015 Nov;16(6):e235-43
pubmed: 26050647
Lung Cancer. 2018 Jul;121:82-90
pubmed: 29858032
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2014 Nov 15;120(22):3446-56
pubmed: 24948110
IET Syst Biol. 2007 Jan;1(1):51-60
pubmed: 17370429
Oncol Rep. 2017 May;37(5):3046-3054
pubmed: 28440452
J Cheminform. 2014 Apr 16;6:13
pubmed: 24735618
Nat Biotechnol. 2007 Oct;25(10):1110-1
pubmed: 17921993
Sci Rep. 2016 Feb 16;6:21146
pubmed: 26879404
Oncol Rep. 2017 Feb;37(2):1219-1226
pubmed: 28035396